High-Throughput Empirical and Virtual Screening To Discover Novel Inhibitors of Polyploid Giant Cancer Cells in Breast Cancer
Open Access
- 5 March 2025
- journal article
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (10) , 5498-5506
Abstract
Therapy resistance in breast cancer is increasingly attributed to polyploid giant cancer cells (PGCCs), which arise through whole genome doubling and exhibit heightened resilience to standard treatments. Characterized by enlarged nuclei and increased DNA content, these cells tend to be dormant under therapeutic stress, driving disease relapse. Despite their critical role in resistance, strategies to effectively target PGCCs are limited, largely due to the lack of high-throughput methods for assessing their viability. Traditional assays lack the sensitivity needed to detect PGCC-specific elimination, prompting the development of novel approaches. To address this challenge, we developed a high-throughput single-cell morphological analysis workflow designed to differentiate compounds that selectively inhibit non-PGCCs, PGCCs, or both. Using this method, we screened a library of 2726 FDA Phase 1-approved drugs, identifying promising anti-PGCC candidates, including proteasome inhibitors, FOXM1, CHK, and macrocyclic lactones. Notably, RNA-Seq analysis of cells treated with the macrocyclic lactone Pyronaridine revealed AXL inhibition as a potential strategy for targeting PGCCs. Although our single-cell morphological analysis pipeline is powerful, empirical testing of all existing compounds is impractical and inefficient. To overcome this limitation, we trained a machine learning model to predict anti-PGCC efficacy in silico, integrating chemical fingerprints and compound descriptions from prior publications and databases. The model demonstrated a high correlation with experimental outcomes and predicted efficacious compounds in an expanded library of over 6,000 drugs. Among the top-ranked predictions, we experimentally validated five compounds as potent PGCC inhibitors using cell lines and patient-derived models. These findings underscore the synergistic potential of integrating high-throughput empirical screening with machine learning-based virtual screening to accelerate the discovery of novel therapies, particularly for targeting therapy-resistant PGCCs in breast cancer.Keywords
All Related Versions
Funding Information
- National Center for Advancing Translational Sciences (UL1TR001857)
- Pittsburgh Liver Research Center, University of Pittsburgh
- National Cancer Institute (3R00CA248944-04S1, P30CA047904, P50CA272218, R00CA248944)
- Magee-Womens Research Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK120531)
- Leukemia Research Foundation
- Hillman Cancer Center, Medical Center, University of Pittsburgh
- National Institute of Dental and Craniofacial Research (R03DE033361)
- Medical Center, University of Pittsburgh
- Office of the Director (S10OD028483)
- National Institute of General Medical Sciences (R35GM150509, R35GM154967)
This publication has 81 references indexed in Scilit:
- Selamectin increases cisplatin sensitivity by inhibiting cisplatin-resistant genes expression and autophagy in uveal melanomaBiochemical and Biophysical Research Communications, 2023
- Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer CellsCancer Cell, 2020
- Pyronaridine: An update of its pharmacological activities and mechanisms of actionBiopolymers, 2020
- Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pigAntiviral Research, 2020
- EMT-related protein expression in polyploid giant cancer cells and their daughter cells with different passages after triptolide treatmentMedical Oncology, 2019
- MicroRNA‐139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXLThe Prostate, 2019
- Disentangling the aneuploidy and senescence paradoxes: a study of triploid breast cancers non-responsive to neoadjuvant therapyHistochemistry and Cell Biology, 2016
- Docetaxel-induced polyploidization may underlie chemoresistance and disease relapseCancer Letters, 2015
- Ubiquitination and downregulation of ErbB2 and estrogen receptor‐alpha by kinase inhibitor MP‐412 in human breast cancer cellsJournal of Cellular Biochemistry, 2011
- A comparison of the efficacy of subcutaneously administered ivermectin, doramectin, and moxidectin against naturally infected Toxocara vitulorum in calvesTropical Animal Health and Production, 2011